AIM ImmunoTech (AIM) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Ascendiant Capital | Maintained | Buy | $7.00 from $9.00 | Aug 20, 2026 |
| Ascendiant Capital | Maintained | Buy | $9.00 from $10.00 | Jun 1, 2026 |
| Ascendiant Capital | Maintained | Buy | $10.00 from $22.00 | Apr 10, 2026 |
| Ascendiant Capital | Maintained | Buy | $22.00 from $24.00 | Dec 8, 2025 |
| Ascendiant Capital | Maintained | Buy | $24.00 from $150.00 | Oct 3, 2025 |
Frequently asked questions
Is AIM a buy, sell, or hold?
Analysts covering AIM ImmunoTech currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on AIM?
On Aug 20, 2026, Ascendiant Capital maintained AIM ImmunoTech at Buy with a price target of $7.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.